Last deal

Amount

Series A

Stage

01.08.2021

Date

1

all rounds

date founded

Financing round

General

About Company
BioChange has developed an injectable scaffold that stimulates tissue repair and regeneration.

Industry

Sector :

Subsector :

founded date

01.05.2015

founders

Number of employees

Last funding type

Series A

IPO status

Private

Description

The company's breakthrough technology for tissue regeneration, based on natural biomaterials, has been validated through long-term animal studies and is currently being sold in the veterinary market and used in tissue engineering research. BioChange is also planning to conduct its first clinical study in aesthetic dermatology in 2022 and has several other products in development to expand its pipeline.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Regentis Biomaterials

Regentis Biomaterials

Regentis Biomaterials develops proprietary hydrogels for tissue regeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Or Akiva, Israel

total rounds

5

total raised

$36.08M
Harbor MedTech

Harbor MedTech

Harbor MedTech develops regenerative devices for tissue healing and repair.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Irvine, CA, USA

total rounds

5

total raised

$15.76M
Kuros Biosciences

Kuros Biosciences

Kuros Biosciences AG is a Swiss company that develops innovative products for tissue repair and regeneration.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

8952 Schlieren, Switzerland

total rounds

9

total raised

$82.17M
Spiderwort

Spiderwort

Spiderwort is a tissue engineering company that develops transformative biomaterials for repairing and regenerating human tissues.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Ottawa, ON, Canada

total rounds

5

total raised

$16.08M

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 01.08.2021. Their latest investor Ariel Yaar. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
01.08.2021
1
Co-Investors
Investors
1
0

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A
Ariel Yaar

Ariel Yaar

current job

Readz
Readz

count Of Investments

5

People

Founders
1
Ishay Attar
Ishay Attar

Ishay Attar

Ishay is the founder of the company and serves as CEO & Chairman, leading it from an idea to a well-established, fast growing company. He has 20 years of experience leading the development of innovative technologies that address large un-met medical needs such as tissue reconstruction, surgical repair, diabetes, glaucoma, dry eye syndrome, and COPD. Ishay was the founder and CEO of LifeBond, a biosurgery startup which was acquired in 2019 by BD-Bard (BDX on NYSE). He holds an MBA, M.Sc in Biomedical engineering, and B.Sc in Biotechnology engineering, all from the Technion, Israel Institute of Technology.

current job

BioChange Ltd.
BioChange Ltd.

organization founded

3

Ishay Attar

Employee Profiles
2
Ofir Artzi

Ofir Artzi

Chief Medical Officer

Ishay Attar

Ishay Attar

Chairman/CEO & Founder

Activity

Recent News
0